Kratom Withdrawal: What a Global Panel of Experts Really Concluded

Kratom has exploded in popularity across the United States and around the world — used for energy, mood, pain relief, and, for many, as a tool to manage opioid withdrawal. But one question keeps surfacing: Does kratom cause physical dependence and withdrawal?

A recent scientific expert forum brought together leading kratom researchers from Johns Hopkins, Yale, Universiti Sains Malaysia, the University of Florida, and others to answer exactly that. Their discussion was published in Drug and Alcohol Dependence Reports, and it offers the clearest picture yet of what science actually shows.

Below is a breakdown of the key findings — in plain language — and what they mean for consumers, clinicians, and policymakers.

A Decade of New Research Has Changed the Conversation

The article notes that “clarity on kratom’s dependence and withdrawal potential increased substantially over the past decade,” thanks to new funding and dozens of fresh studies. These include:

• Animal studies comparing kratom’s main alkaloid, mitragynine, to opioids
• Clinical trials using validated withdrawal scales
• U.S. and Southeast Asian user surveys
• Case reports from treatment settings

Together, these paint a surprisingly consistent picture.

What the Experts Agree On

1. Kratom Can Cause Physical Dependence — But Usually Mild

Across surveys, only a minority of users report withdrawal symptoms when stopping kratom. One U.S. survey found fewer than 10% experienced withdrawal, and those who did often had a history of opioid use.

The paper states:

“Withdrawal was reported by some taking high amounts of kratom products… likely exceeding 300 mg mitragynine per day.”

In other words, dose matters. Moderate daily use (e.g., 2 grams once or twice a day) rarely produces withdrawal.

2. Kratom Withdrawal Looks Different From Opioid Withdrawal

Animal studies show that withdrawal from mitragynine is weaker and qualitatively different from morphine or heroin. Human reports match this:

• Some symptoms resemble opioids (runny nose, muscle aches, diarrhea)
• Others resemble sedatives or stimulants (lethargy, anxiety, low mood)

Overall, symptoms are described as “milder… more tolerable and self-manageable.”

3. People Commonly Use Kratom to Manage Opioid Withdrawal

Both U.S. and Southeast Asian data show many consumers use kratom to:

• Reduce opioid cravings
• Ease withdrawal
• Maintain abstinence

Interestingly, kratom’s ability to reduce opioid withdrawal may come not only from its partial opioid activity but also from alpha‑adrenergic effects, similar to medications like clonidine and lofexidine.

4. Controlled Clinical Studies Found No Withdrawal

Two formal clinical studies — including one approved by Health Canada — used gold‑standard withdrawal scales (COWS and SOWS). They found:

“No significant differences… in withdrawal scores or adverse events.”

Even long‑term daily kratom users showed no measurable withdrawal after stopping for the study.

5. Kratom’s Many Alkaloids Matter

Kratom contains 40+ alkaloids, not just mitragynine. Some may reduce withdrawal, others may contribute to it. Products with artificially boosted alkaloid levels could behave differently than natural leaf.

What the Experts Recommend Next

The forum outlined several research priorities:

1. Better Dose‑Response Data

We need clearer thresholds for “moderate,” “heavy,” and “high‑risk” kratom use.

2. New Withdrawal Assessment Tools

Because kratom’s withdrawal profile differs from opioids, opioid‑specific scales may miss important symptoms.

3. Study Non‑Opioid Treatments

Since kratom withdrawal is usually mild, first‑line treatments should be non‑opioid options like:

• Lofexidine
• Clonidine
• Gradual tapering

4. Understand Who Is Most at Risk

People with prior opioid use appear more likely to report kratom withdrawal. Researchers want to understand why.

Why This Matters Now

The authors emphasize urgency:

“The toll of opioid overdose deaths continues to increase… research is urgent.”

Kratom is widely used as an informal harm‑reduction tool, but it is not FDA‑approved for treating opioid withdrawal or any medical condition. Understanding its true risks and benefits is essential for:

• Public health policy
• Product regulation
• Future development of safer pain‑relief and addiction‑treatment medications

Bottom Line

The expert forum’s conclusions are clear:

• Kratom can cause physical dependence, but usually at high doses and with milder withdrawal than opioids.
• Most moderate users do not experience withdrawal.
• Many people use kratom successfully to manage opioid withdrawal, though more research is needed.
• Clinical studies so far have not detected measurable withdrawal using standard tools.
• Kratom’s pharmacology is complex, involving multiple receptor systems beyond opioids.

Kratom isn’t risk‑free — but it also isn’t behaving like traditional opioids. As research continues, kratom may help shape the future of safer pain and addiction treatments.